Voclosporin
FDA-approved product (capsule, oral), marketed as Lupkynis.
- Registered studies
- 28
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Immune system disease
- Lupus nephritis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Calcineurin inhibitors
- FDA pharmacologic class
- Calcineurin Inhibitor Immunosuppressant FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
28registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Voclosporin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pafolacianine SodiumExisting use: Other diagnostic agents47.8% AI-predicted activityagainst K. pneumoniae1 registered study
- Rezafungin AcetateExisting use: Candidemia, Candidiasis, Candidiasis, Invasive47.6% AI-predicted activityagainst K. pneumoniae5 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection47.3% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Ergoloid MesylatesExisting use: Cardiovascular disease47.1% AI-predicted activityagainst K. pneumoniae2 registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more47.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma47.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more46.7% AI-predicted activityagainst K. pneumoniae35 registered studies
- Hydrocodone BitartrateExisting use: Cough, Drug dependence, Pain46.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more46.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- AnidulafunginExisting use: Candidemia, Candidiasis, Peritonitis46.1% AI-predicted activityagainst K. pneumoniae43 registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more46.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Dihydroergotamine MesylateExisting use: Migraine disorder46.0% AI-predicted activityagainst K. pneumoniae21 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Aurinia Renal Response in Active Lupus With Voclosporin
NCT03021499 · start 2017-05-17
Registered record
- Registry ID
- NCT03021499
- Conditions
- Lupus Nephritis
- Interventions
- Voclosporin; Placebo Oral Capsule
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-05-17
- Completion
- 2019-10-10
- Enrolment
- 358
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLupus NephritisInterventionVoclosporin; Placebo Oral CapsulePhasePhase 3Registry statusCompletedVoclosporin in Healthy Japanese Volunteers
NCT02949999 · start 2016-10
Registered record
- Registry ID
- NCT02949999
- Conditions
- Volunteers
- Interventions
- Voclosporin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-10
- Completion
- 2016-12
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVolunteersInterventionVoclosporinPhasePhase 1Registry statusCompletedAurinia Early Urinary Protein Reduction Predicts Response
NCT02949973 · start 2015-06
Registered record
- Registry ID
- NCT02949973
- Conditions
- Lupus Nephritis
- Interventions
- voclosporin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-06
- Completion
- 2017-02-17
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLupus NephritisInterventionvoclosporinPhasePhase 2Registry statusCompletedAURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
NCT02141672 · start 2014-06
Registered record
- Registry ID
- NCT02141672
- Conditions
- Lupus Nephritis
- Interventions
- Voclosporin High Dose; Voclosporin Low Dose; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-06
- Completion
- 2017-01
- Enrolment
- 265
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLupus NephritisInterventionVoclosporin High Dose; Voclosporin Low Dose; PlaceboPhasePhase 2Registry statusCompletedSafety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation
NCT01586845 · start 2013-03
Registered record
- Registry ID
- NCT01586845
- Conditions
- Renal Transplantation
- Interventions
- voclosporin; tacrolimus
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Withdrawn
- Start
- 2013-03
- Completion
- 2015-12
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRenal TransplantationInterventionvoclosporin; tacrolimusPhasePhase 3Registry statusWithdrawnEfficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis
NCT01243983 · start 2011-02
Registered record
- Registry ID
- NCT01243983
- Conditions
- Noninfectious Uveitis
- Interventions
- LX211
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2012-12
- Enrolment
- 155
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNoninfectious UveitisInterventionLX211PhasePhase 3Registry statusCompletedA Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
NCT00851734 · start 2009-02
Registered record
- Registry ID
- NCT00851734
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- voclosporin ophthalmic solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-02
- Completion
- 2009-04
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKeratoconjunctivitis SiccaInterventionvoclosporin ophthalmic solutionPhasePhase 1Registry statusCompletedCOronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms (CONFIRM 1)
NCT00689767 · start 2008-06
Registered record
- Registry ID
- NCT00689767
- Conditions
- Coronary Artery Disease
- Interventions
- CINATRA™ Coronary Stent System; CINATRA™ ISA 247 Coated Coronary Stent System
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2008-06
- Completion
- 2012-07
- Enrolment
- 103
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionCINATRA™ Coronary Stent System; CINATRA™ ISA 247 Coated Coronary Stent SystemPhaseNot applicableRegistry statusTerminatedRandomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients
NCT00408187 · start 2006-12
Registered record
- Registry ID
- NCT00408187
- Conditions
- Psoriasis
- Interventions
- voclosporin; Ciclosporin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-12
- Completion
- 2008-12
- Enrolment
- 642
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsoriasisInterventionvoclosporin; Ciclosporin; PlaceboPhasePhase 3Registry statusCompletedStudy of ISA247 (Voclosporin) in De Novo Renal Transplantation
NCT00270634 · start 2006-01
Registered record
- Registry ID
- NCT00270634
- Conditions
- Kidney Diseases
- Interventions
- Voclosporin; tacrolimus
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-01
- Completion
- 2009-07
- Enrolment
- 334
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney DiseasesInterventionVoclosporin; tacrolimusPhasePhase 2Registry statusCompletedA 36-Week Extension to Protocol ISA04-03
NCT00258713 · start 2005-09
Registered record
- Registry ID
- NCT00258713
- Conditions
- Psoriasis
- Interventions
- voclosporin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2006-07
- Enrolment
- 309
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsoriasisInterventionvoclosporinPhasePhase 3Registry statusCompletedRandomized Placebo-controlled Study of ISA247 in Plaque Psoriasis
NCT00244842 · start 2004-12
Registered record
- Registry ID
- NCT00244842
- Conditions
- Psoriasis
- Interventions
- voclosporin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-12
- Completion
- 2005-10
- Enrolment
- 451
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsoriasisInterventionvoclosporin; PlaceboPhasePhase 3Registry statusCompletedSpecial Access for the Use of Voclosporin for Kidney Transplantation
NCT01236287
Registered record
- Registry ID
- NCT01236287
- Conditions
- Immunosuppression; Transplantation, Kidney
- Interventions
- Voclosporin
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- No longer available
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImmunosuppression; Transplantation, KidneyInterventionVoclosporinPhaseNot recordedRegistry statusNo longer available